|
|
Strategic Perspectives 2001: Dementia - Commercial Opportunities in Unfamiliar TerritoryPublished by: Datamonitor Published: Jan. 3, 2002 - 171 Pages Table of ContentsStrategic Perspectives 2001: Dementia - Commercial Opportunities in Unfamiliar Territory DATAMONITOR HEALTHCARE EXECUTIVE SUMMARY Scope Datamonitor insight into the dementia markets VaD is the second most common form of dementia after AD, affecting over four million people in the seven major markets. There are no approved drugs for VaD, although companies currently marketing AD products are likely to launch their drugs in 2003. Further drug launches will contribute to the rapid growth of this attractive market, which is predicted to be worth $1.9bn in 2008. DLB is the third most prevalent dementia, although it has only recently become recognized as a clinical entity. Consequently, DLB is associated with very low diagnosis rates. However, physicians diagnosing DLB commonly prescribe AChEIs off label. Novartis is in the process of gaining approval for Exelon for a 2002 launch and will initially dominate the market, which is expected to be worth $490m in 2008. Although antiviral combinations can prevent ADC, and sometimes reverse it, there remains a strong unmet need for cognition enhancing drugs. The most promising candidates thus far are NMDA antagonists and MAO inhibitors. Estimated to be worth $119m in 2008, ADC is clearly a niche market ideal for small pharmaceutical companies marketing antidementia drugs. BPSD affect over 80% of dementia patients, and are widely regarded as the most distressing symptoms for both patient and caregiver. The greatest opportunity for pharmaceutical companies lies in the treatment of psychosis and aggression with atypical neuroleptics. For example, sales of drugs in this class are expected to reach $714m in 2008 for the treatment of delusions in dementia patients. Key metrics TABLE OF CONTENTS EPIDEMIOLOGY Dementia overview Diagnostic criteria Etiology Symptomology Comorbidities Prevalence Sex differences Regional differences Epidemiological conclusion CLINICAL PRACTICE Introduction Diagnosis Diagnostic procedures Comprehensive patient evaluation Differential diagnosis Treatment Treatment aims Treatment guidelines Pharmacological treatment of dementia Management of BPSD Non-pharmacological management Summary of treatment Patient potential VASCULAR DEMENTIA MARKET Introduction Reminyl Aricept Memantine Summary of trials Summary of clinical research Competitive analysis The global vascular dementia market, 2001 Key market drivers Drug launches Heart protection study International Congress on VaD The future decoded Epidemiological forecasts to 2008 Global market forecasts Unmet needs DEMENTIA WITH LEWY BODIES MARKET Introduction Exelon The global DLB market, 2001 Key market drivers Drug launches The aging population Awareness The future decoded Epidemiological forecasts to 2008 Global market forecasts Unmet needs AIDS DEMENTIA COMPLEX MARKET Introduction NMDA antagonists Platelet activating factor antagonists Anti-inflammatory agents MAO inhibitors Calcium channel blockers Nucleoside analogs HAART Summary of other pipeline ADC drugs Summary of trials The global ADC market, 2001 Key market drivers Launch of non-antiviral drugs Current attitudes and awareness DTC advertising and the Internet Patient power The future decoded Epidemiological forecasts to 2008 Global market forecasts Unmet needs THE BPSD MARKET Introduction Antipsychotics Anticonvulsants Competitive analysis Summary of trials The global BPSD market Delusions Depression Anxiety Hallucinations Aggression Summary of current BPSD drug sales Key market drivers The aging population Overuse of antipsychotics Underuse of antidepressants Caregiver burden The future decoded Epidemiological forecasts to 2008 Global market forecasts Delusions Depression Anxiety Hallucinations Aggression Summary of BPSD forecasts Unmet needs APPENDIX Summary of pipeline antidementia drugs Datamonitor's Central Nervous System Business Unit Contributing experts Table of tables Table of figures Bibliography References Websites Pricing data Introduction Source prices Ex-manufacturer, wholesaler and retail prices Data validation and margin calculation Quality control Exchange rates Patent expiries (c) Datamonitor 2002. All Rights Reserved. AbstractStrategic Perspectives 2001: Dementia provides comprehensive analysis of the main forms of non-Alzheimer dementias, utilizing key epidemiological and clinical data to determine where the main pharmaceutical opportunities lie across the seven major markets. The dementia types covered include vascular dementia (VaD), dementia with Lewy bodies (DLB) and AIDS dementia complex (ADC).Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||